跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 112 条关于
“BioChaperone CagriSema”
全部
112
临床试验
54
药物
9
机构
1
资讯
48
10个月前
Adocia Files Patent for AdoXLong Platform to Extend Peptide Therapy Duration to Monthly Injections
去年
Adocia Secures €9.7 Million Private Placement to Advance Diabetes and Obesity Pipeline Through Q2 2026
3个月前
Adocia to Host Virtual KOL Event Reviewing Phase 3 Results of Ultra-Rapid Insulin BioChaperone Lispro in Type 2 Diabetes
去年
Adocia's Ultra-Rapid Insulin BioChaperone Lispro Meets Primary Endpoint in Phase 3 Trial for Type 2 Diabetes
去年
Novo’s CagriSema Disappoints in Pivotal Trial
去年
Novo Nordisk Delays CagriSema Obesity Drug Filing to Early 2026
9个月前
Novo Nordisk's CagriSema Falls Short Against Eli Lilly's Tirzepatide in Obesity Trial
去年
CagriSema Fails to Meet Primary Endpoint in Phase III Clinical Trial for Obesity
9个月前
Novo Nordisk's CagriSema Outperforms Ozempic in Diabetes Trial, Company Plans Pediatric Obesity Study
去年
Novo Nordisk's CagriSema Shows Promise in Weight Loss and Diabetes Treatment
第 1 页,共 5 页
上一页
下一页